DNA Script strengthens its management team with the appointment of Bruno Poddevin as Senior Vice President of Business and Corporate Development

Poddevin joins DNA Script in a year of immense growth in hiring, financing, commercialization and collaborations.

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, further strengthened its leadership team with the addition of Bruno Poddevin, Ph.D., who brings 30 years of experience in the oligo manufacturing industry to the role of Senior VP, Business and Corporate Development.

In his new position, Poddevin will manage DNA Script’s external collaborations and partnerships, targeting a faster integration of EDS into established as well as innovative molecular biology and synthetic biology processes.

“DNA Script has achieved significant growth since its founding 8 years ago, and we are now in the next phase of becoming the global leader in EDS on demand,” said Thomas Ybert, Ph.D., CEO and cofounder. “Business development is a strong emphasis and key growth driver for our business, and Bruno brings both depth and breadth of experience and his established network to aid in expanding our market presence and realizing our global development strategies.”

Poddevin has spent his professional career in the oligos industry, having held responsibilities in several pioneering DNA synthesis companies including Genset Oligos, Proligo, Sigma Genosys, MWG Biotech and Operon Biotechnologies. Over the 15 past years he initiated and managed the Genomic Services branch of Eurofins, where he helped translate DNA-based technologies into business applications serving a broad range of market segments including food, environment, pharma testing and clinical genetics testing as well as agro- and forensic sciences. Poddevin holds a Master of Engineering and a Ph.D. in molecular biology.

“In less than 10 years EDS has reached the level of performance that chemical DNA synthesis took 50 years to reach. Each technology iteration further improves its performance. It is clear that this technology will solve problems that traditional DNA synthesis methods could not solve, opening new avenues for using DNA in applications that have thus far been inaccessible, all of it in a more environmentally friendly way,” said Poddevin. “DNA Script is the leader of this new way of making DNA, and I am very excited to join this young and energetic team and contribute to making this next generation of oligo synthesis broadly available.”

Poddevin joins DNA Script in a year where the company has seen immense growth in hiring, financing, commercialization and collaborations. In early 2022 the company announced a $200 million Series C investment round. They continued this momentum with an expansion of their global presence in Asia Pacific and the Middle East for the sale, distribution and support of its products through distribution agreements as well as the launch of new synthesis kits enabling longer oligos and modifications. The company announced continued collaborations with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), to detect and diagnose new pathogens, and a partnership with Wellcome Leap to accelerate the development of RNA-based products, including messenger RNA vaccines. Most recently, DNA Script received the Grand Prize Trophy at the 2022 French Future Unicorns Ceremony.

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com

Contact

publicrelations@dnascript.co